Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).

ABSTRACT:

Background

In the United States, patients who enroll in chemotherapy trials seldom reflect the attributes of the general population with cancer, as they are often younger, more functional, and have less comorbidity. We compared survival following three chemotherapy regimens according to the setting in which care was delivered (ie, clinical trial vs usual care) to determine the generalizability of clinical trial results to unselected elderly Medicare patients.

Methods

Using SEER-Medicare data, we estimated survival for elderly patients (ie, age 65 years or older, n = 14097) with advanced pancreatic or lung cancer following receipt of one of three guideline-recommended first-line chemotherapy regimens. We compared their survival to that of similarly treated clinical trial enro

SUBMITTER: Lamont EB 

PROVIDER: S-EPMC4271075 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature